Endocrine Abstracts

Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men and a leading cause of male mortality. The androgen receptor (AR) remains the major therapeutic target with therapies that inhibit the AR signaling axis improving the outcome for patients with advanced castration-sensitive and castration-resistance prostate cancer. Despite these advances, primary and secondary resistance to AR targeting therapies is common, with evidence of ongoing AR signaling in t...

Prostate cancer (PCa) is one of the most common endocrine-related cancers (ERCs) among men worldwide. The aggressiveness of this tumor pathology is highly influenced by different endocrine-related factors, highlighting the crucial role of androgens. Therefore, the main therapeutic approach for PCa patients is based on the pharmacological blockade of androgen-signaling. However, some patients become unresponsive and develop a highly lethal castration-resistant disease, pointing...

Background: Treatment resistance in prostate cancer can be the result of multiple different tumour cell adaptations generating castration-resistant prostate cancer (CRPC). Despite advancements in treatment, CRPC remains a highly lethal disease. Some CRPCs become AR independent with loss of AR expression and lineage plasticity, urgently requiring novel therapeutic strategies. BCL2 can be upregulated in some CRPCs and may be a therapeutic target for this disease subset.<p cl...